First in the field to exclusively cover the link between diabetes and cardiovascular disorders, Cardiovascular Diabetology is the leading, international open access journal specifically dedicated to exploring the interrelationship between heart diseases and alterations in glucose metabolism. With a rigorous peer review process and a quick time to first decision, Cardiovascular Diabetology provides high visibility and ample global exposure to showcase the extraordinary breakthroughs in clinical, genetic, experimental, pharmacological, epidemiological, and molecular biology research with one goal in mind, to improve public health in the cardiocirculatory and diabetic landscape.
Cardiovascular Diabetology
Description
Identifiers
e-ISSN | 1475-2840 |
Publisher
BioMed Central
Additional information
Data set: Springer
Articles
Cardiovascular Diabetology > 2019 > 18 > 1 > 1-11
Background Despite revascularisation, a large proportion of acute coronary syndrome (ACS) patients continue to experience major adverse cardiovascular events (MACEs), which are worsened by diabetes mellitus (DM). Fibrinogen (FIB) is a risk factor for MACEs in coronary artery disease and often elevated in DM. However, the relationships between FIB, glucose metabolism (haemoglobin A1c [HbA1c] and fasting...
Cardiovascular Diabetology > 2019 > 18 > 1 > 1-9
Background Prediabetes is a well-established risk factor for progression to overt diabetes mellitus (DM), which is in turn associated with development of hypertension (HTN) and vice versa. However, the role of prediabetes and HbA1c in particular as an independent risk factor for the development of hypertension is unclear. Aim In this current study, we aimed to evaluate the association between both...
Cardiovascular Diabetology > 2019 > 18 > 1 > 1-9
With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) is considered an independent risk factor for the development of CAD. Metformin, an anti-diabetic drug, has been shown in pre-clinical and clinical studies, to lower the cardiovascular events in...